Pancreatic Tumor Management

Diagnostic Approach

For a young to middle-aged adult with rheumatic heart disease presenting with a pancreatic tumor, the American College of Cardiology recommends proceeding directly with contrast-enhanced multi-detector CT (MD-CT) of the chest, abdomen, and pelvis using a pancreatic protocol, combined with baseline CA 19-9 measurement and liver function tests to establish resectability status 1
The European Society for Medical Oncology suggests that abdominal ultrasound may have been performed initially but is insufficient for definitive evaluation 2
MD-CT with triphasic imaging (late arterial and portal venous phases) using 3mm thin slices provides >90% positive predictive value for determining resectability, according to the National Comprehensive Cancer Network 1, 3

For resectable disease, the American Society of Clinical Oncology recommends proceeding directly to surgery without preoperative biopsy if imaging confirms resectable disease and the patient is a surgical candidate 1, 3
The National Comprehensive Cancer Network suggests that pancreatic head tumors should be treated with partial pancreaticoduodenectomy (Whipple procedure) 2, 1
For borderline resectable disease, the European Society for Medical Oncology recommends considering neoadjuvant chemotherapy (gemcitabine plus nab-paclitaxel) to achieve tumor downsizing and conversion to resectable status, particularly if CA 19-9 >500 IU/ml 1, 4, 3

The American Society of Clinical Oncology recommends that all patients who undergo resection must receive 6 months of adjuvant chemotherapy with gemcitabine 1000 mg/m² over 30 minutes weekly for 7 weeks, then one week rest, followed by weekly dosing on Days 1, 8, and 15 of 28-day cycles, or 5-FU 2, 1
Adjuvant chemotherapy improves 5-year survival from approximately 9% to 20%, according to the National Comprehensive Cancer Network 4

The American College of Radiology recommends monitoring CA 19-9 every 3 months for 2 years if preoperatively elevated 3
The National Comprehensive Cancer Network suggests that CA 19-9 should be used to assess treatment response during chemotherapy 3
Lymph node ratio (LNR) ≥0.2 indicates worse prognosis, according to the American Joint Committee on Cancer 1, 4